Paul Herendeen, Director at Elanco Animal Health Inc (ELAN), bought 10,000 shares at $23.68 ($237K) on 2026-08-07, disclosed to the SEC on 2026-08-10.
Director Paul Herendeen purchased $236,850 worth of ELAN stock at $23.68, marking the largest insider purchase in the company's history, which may signal confidence in the stock's rebound potential following recent volatility. This move comes shortly after the company reported strong Q2 earnings driven by blockbuster products like Zenrelia and Credelio Quattro.
The stock is currently trading at $22.30, down 13.23% over the last 5 days and 10.15% over the last 30 days, but remains up 33.77% over the past year and is 20.24% below its 52-week high of $27.96.
1) Q2 2026 earnings on August 5, 2026, which saw earnings and revenue beat estimates by 25.93% and 4.41% respectively. 2) FDA Emergency Use Authorization for CLiK Extra wound spray on August 10, 2026. 3) Raised full-year revenue guidance to US$5,090 million–US$5,140 million announced on August 10, 2026.
The stock is currently down 16.12% over the past seven days, indicating recent selling pressure that could persist despite the insider purchase. Additionally, the stock has a short interest of 11.45% of the float, which could add volatility if the stock begins to recover.
Nothing distinguishes this filing.
| Filing → |
| VRX | BUY | 2018-03-13 | $483K | — | Filing → |
| VRX | BUY | 2017-03-16 | $515K | — | Filing → |
| WCRX | SELL | 2013-03-01 | $63K | — | Filing → |